Cargando…

Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers

Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for l...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bo, Chen, Hui, Yang, Shaohua, Chen, Feng, Xu, Liangliang, Li, Yan, Li, Mingzhe, Zhu, Chengming, Shao, Fangyuan, Zhang, Xinhua, Deng, Chuxia, Zeng, Leli, He, Yulong, Zhang, Changhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111719/
https://www.ncbi.nlm.nih.gov/pubmed/37072770
http://dx.doi.org/10.1186/s12943-023-01770-6
_version_ 1785027505236738048
author Li, Bo
Chen, Hui
Yang, Shaohua
Chen, Feng
Xu, Liangliang
Li, Yan
Li, Mingzhe
Zhu, Chengming
Shao, Fangyuan
Zhang, Xinhua
Deng, Chuxia
Zeng, Leli
He, Yulong
Zhang, Changhua
author_facet Li, Bo
Chen, Hui
Yang, Shaohua
Chen, Feng
Xu, Liangliang
Li, Yan
Li, Mingzhe
Zhu, Chengming
Shao, Fangyuan
Zhang, Xinhua
Deng, Chuxia
Zeng, Leli
He, Yulong
Zhang, Changhua
author_sort Li, Bo
collection PubMed
description Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for localized GISTs and recurrent/metastatic GISTs, respectively. Despite multi-lines of TKIs treatments prolonged the survival time of recurrent/metastatic GISTs by delaying the relapse and metastasis of the tumor, drug resistance developed quickly and inevitably, and became the huge obstacle for stopping disease progression. Immunotherapy, which is typically represented by immune checkpoint inhibitors (ICIs), has achieved great success in several solid tumors by reactivating the host immune system, and been proposed as an alternative choice for GIST treatment. Substantial efforts have been devoted to the research of immunology and immunotherapy for GIST, and great achievements have been made. Generally, the intratumoral immune cell level and the immune-related gene expressions are influenced by metastasis status, anatomical locations, driver gene mutations of the tumor, and modulated by imatinib therapy. Systemic inflammatory biomarkers are regarded as prognostic indicators of GIST and closely associated with its clinicopathological features. The efficacy of immunotherapy strategies for GIST has been widely explored in pre-clinical cell and mouse models and clinical experiments in human, and some patients did benefit from ICIs. This review comprehensively summarizes the up-to-date advancements of immunology, immunotherapy and research models for GIST, and provides new insights and perspectives for future studies.
format Online
Article
Text
id pubmed-10111719
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101117192023-04-19 Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers Li, Bo Chen, Hui Yang, Shaohua Chen, Feng Xu, Liangliang Li, Yan Li, Mingzhe Zhu, Chengming Shao, Fangyuan Zhang, Xinhua Deng, Chuxia Zeng, Leli He, Yulong Zhang, Changhua Mol Cancer Review Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human health and economy globally. Curative surgical resections and tyrosine kinase inhibitors (TKIs) are the main managements for localized GISTs and recurrent/metastatic GISTs, respectively. Despite multi-lines of TKIs treatments prolonged the survival time of recurrent/metastatic GISTs by delaying the relapse and metastasis of the tumor, drug resistance developed quickly and inevitably, and became the huge obstacle for stopping disease progression. Immunotherapy, which is typically represented by immune checkpoint inhibitors (ICIs), has achieved great success in several solid tumors by reactivating the host immune system, and been proposed as an alternative choice for GIST treatment. Substantial efforts have been devoted to the research of immunology and immunotherapy for GIST, and great achievements have been made. Generally, the intratumoral immune cell level and the immune-related gene expressions are influenced by metastasis status, anatomical locations, driver gene mutations of the tumor, and modulated by imatinib therapy. Systemic inflammatory biomarkers are regarded as prognostic indicators of GIST and closely associated with its clinicopathological features. The efficacy of immunotherapy strategies for GIST has been widely explored in pre-clinical cell and mouse models and clinical experiments in human, and some patients did benefit from ICIs. This review comprehensively summarizes the up-to-date advancements of immunology, immunotherapy and research models for GIST, and provides new insights and perspectives for future studies. BioMed Central 2023-04-18 /pmc/articles/PMC10111719/ /pubmed/37072770 http://dx.doi.org/10.1186/s12943-023-01770-6 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Li, Bo
Chen, Hui
Yang, Shaohua
Chen, Feng
Xu, Liangliang
Li, Yan
Li, Mingzhe
Zhu, Chengming
Shao, Fangyuan
Zhang, Xinhua
Deng, Chuxia
Zeng, Leli
He, Yulong
Zhang, Changhua
Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
title Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
title_full Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
title_fullStr Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
title_full_unstemmed Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
title_short Advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
title_sort advances in immunology and immunotherapy for mesenchymal gastrointestinal cancers
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10111719/
https://www.ncbi.nlm.nih.gov/pubmed/37072770
http://dx.doi.org/10.1186/s12943-023-01770-6
work_keys_str_mv AT libo advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT chenhui advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT yangshaohua advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT chenfeng advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT xuliangliang advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT liyan advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT limingzhe advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT zhuchengming advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT shaofangyuan advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT zhangxinhua advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT dengchuxia advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT zengleli advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT heyulong advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers
AT zhangchanghua advancesinimmunologyandimmunotherapyformesenchymalgastrointestinalcancers